The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status (ADEPPT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05673187
Recruitment Status : Recruiting
First Posted : January 6, 2023
Last Update Posted : April 9, 2024
Sponsor:
Collaborator:
Mirati Therapeutics Inc.
Information provided by (Responsible Party):
ETOP IBCSG Partners Foundation

Brief Summary:
ADEPPT is an international, multicentre, single-arm phase II trial. The protocol treatment consists of adagrasib, which is administered at a dose of 600 mg orally, twice daily until progression or unacceptable toxicity.The primary objective of this trial is to assess the clinical efficacy of adagrasib treatment, in terms of objective response, in patients with KRASG12C-mutant NSCLC, including the elderly (≥70 years) or patients with poor performance status (ECOG PS=2).

Condition or disease Intervention/treatment Phase
NSCLC Stage IV KRAS P.G12C Drug: Adagrasib Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 68 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicentre, Single-arm Phase II Trial of Adagrasib in Patients With KRASG12C-mutant NSCLC, Including the Elderly (≥70 Years) or Patients With Poor Performance Status
Actual Study Start Date : June 12, 2023
Estimated Primary Completion Date : October 1, 2025
Estimated Study Completion Date : March 1, 2026

Arm Intervention/treatment
Experimental: Treatment Arm
Adagrasib to be administered at a dose of 600 mg orally, twice daily until progression or unacceptable toxicity.
Drug: Adagrasib
Adagrasib is administered at a dose of 600 mg orally, twice daily until progression or unacceptable toxicity.




Primary Outcome Measures :
  1. Objective Response Rate (ORR) per RECIST v1.1, assessed at 12 weeks. [ Time Frame: From date of enrolment until 12 weeks post-enrolment ]
    The primary objective of this trial is to assess the clinical efficacy of adagrasib treatment, in terms of objective response as defined as the rate of patients achieving a best overall response [complete response (CR) or partial response (PR)] according to RECIST v1.1


Secondary Outcome Measures :
  1. Durable clinical benefit [ Time Frame: From date of enrolment until at least the 24-week assessment. ]
    Durable clinical benefit (DCB) is defined as the rate among all enrolled patients who are alive and without disease progression who achieve CR or PR, according to RECIST v1.1, or stable disease (SD) lasting for at least 24 weeks.

  2. Time-to-progression (TTP) [ Time Frame: From the date of enrolment until last tumour assessment (approximately 20-26 months after enrolment of the first patient) ]
    Time-to-progression (TTP) is defined as the time from the date of enrolment until the date of documented progression (according to RECIST v1.1). Censoring for patients without documented progression will occur at the date of last tumour assessment without PD. Patients without a post-baseline tumour assessment will be censored at the date of enrolment plus 1 day.

  3. Progression-free survival (PFS) [ Time Frame: From the date of enrolment until last tumour assessment (approximately 20-26 months after enrolment of the first patient) ]
    Progression-free survival (PFS) is defined as the time from the date of enrolment until the date of documented progression (according to RECIST v1.1) or death, if progression is not documented. Censoring (for patients without progression or death) will occur at the date of last tumour assessment. Patients without a post-baseline tumour assessment will be censored at the date of enrolment plus 1 day.

  4. Overall survival (OS) [ Time Frame: From the date of enrolment until last patient last visit (approximately 20-26 months after enrolment of the first patient) ]
    Overall survival (OS) is defined as the time from the date of enrolment until the date of death from any cause. Censoring for patients who are not reported as dead will occur at the last date they are known to be alive. Data for patients who do not have post-baseline information will be censored at the date of enrolment plus 1 day.

  5. Safety and tolerability [ Time Frame: From the date of enrolment until last patient last visit (approximately 20-26 months after enrolment of the first patient) ]

    The toxicity and safety profile of the protocol treatment will be evaluated by:

    • Adverse events (AEs) according to CTCAE v5.0 (any-cause, as well as treatment-related) including AEs leading to dose delays and/or interruptions, withdrawal of protocol treatment, and death
    • Severe and serious AEs
    • Deaths

  6. Laboratory parameters and abnormalities 1 [ Time Frame: From the date of enrolment until last patient last visit (approximately 20-26 months after enrolment of the first patient) ]
    Hemoglobin [g/dl]

  7. Laboratory parameters and abnormalities 2 [ Time Frame: From the date of enrolment until last patient last visit (approximately 20-26 months after enrolment of the first patient) ]
    Platelet count [G/L]

  8. Laboratory parameters and abnormalities 3 [ Time Frame: From the date of enrolment until last patient last visit (approximately 20-26 months after enrolment of the first patient) ]
    White blood cell count [G/L]

  9. Vital signs 1 [ Time Frame: From the date of enrolment until last patient last visit (approximately 20-26 months after enrolment of the first patient) ]
    Blood pressure systolic [mmHg]

  10. Vital signs 2 [ Time Frame: From the date of enrolment until last patient last visit (approximately 20-26 months after enrolment of the first patient) ]
    Blood pressure diastolic [mmHG]

  11. Vital signs 3 [ Time Frame: From the date of enrolment until last patient last visit (approximately 20-26 months after enrolment of the first patient) ]
    Heart rate [beats/min]

  12. Vital signs 4 [ Time Frame: From the date of enrolment until last patient last visit (approximately 20-26 months after enrolment of the first patient) ]
    Body temperature [°C]

  13. Patient-reported outcomes NFLSI-17 [ Time Frame: From the date of screening until patient's end of treatment (approximately 20-26 months after enrolment of the first patient) ]
    Patient-reported symptoms and functioning will be assessed by NCCN-Functional Assessment of Cancer Therapy (FACT) Lung Symptom Index-17 (NFLSI-17).

  14. Patient-reported outcomes PRO-CTCAE® [ Time Frame: From the date of screening until patient's end of treatment (approximately 20-26 months after enrolment of the first patient) ]
    The most commonly reported treatment-related adverse effects of adagrasib (diarrhoea and vomiting) that are not covered by the NFLSI-17 will be assessed by the NCI Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically or cytologically confirmed stage IV NSCLC.
  2. KRASG12C-mutation by local testing (by tissue or ctDNA).
  3. Prior treatment with at least one line of systemic therapy for NSCLC (e.g., platinum-based doublet chemotherapy and/or immune-checkpoint inhibition or both).
  4. Life expectancy ≥12 weeks.
  5. Measurable disease according to RECIST v1.1.
  6. Age ≥18 years with ECOG PS 2 (cohort 1), or age ≥70 years with ECOG PS 0-1 (cohort 2).
  7. Adequate haematological, renal and liver function
  8. Men and women of childbearing potential must agree to use use highly effective contraceptive methods.
  9. Women of childbearing potential, including women who had their last menstruation in the last 2 years, must have a negative urinary or serum beta HCG pregnancy test within 5 weeks before enrolment. Pregnancy test must be repeated within 7 days before the first dose of adagrasib treatment.Ability to comply with the trial protocol, in the investigator's judgment.
  10. Written IC for study participation must be signed and dated by the patient and the investigator prior to any study-related intervention, including the submission of mandatory biomaterial.

Exclusion Criteria:

  1. Prior investigational therapy within 28 days or at least 5 half-lives before enrolment.
  2. Prior treatment with an agent targeting KRASG12C.
  3. Leptomeningeal disease or untreated brain metastases.

    • Patient should be neurologically stable for at least 2 weeks before enrolment, without the need for corticosteroids, except for prednisone (or its equivalent) at a dose of ≤10 mg daily.
    • For patients with definitively treated brain metastases, a time period of minimum of 2 weeks must have elapsed from the last day of radiotherapy.
  4. History of intestinal disease or major gastric surgery likely to alter absorption of study treatment or inability to swallow oral medications.
  5. Any of the following cardiac abnormalities:

    • Unstable angina pectoris or myocardial infarction within 6 months prior to enrolment.
    • Symptomatic or uncontrolled atrial fibrillation within 6 months prior to enrolment.
    • Congestive heart failure ≥NYHA Class 3 within 6 months prior to enrolment.
    • Prolonged QTc interval >480 ms or family or medical history of congenital Long QT Syndrome.
  6. History of stroke or transient ischemic attack within 6 months prior to enrolment.
  7. Ongoing need for treatment with concomitant medication with any of the following characteristics: known risk of Torsades de Pointes; substrate of CYP3A with narrow therapeutic index; strong inducer of CYP3A and/or P-gp; strong inhibitor of BCRP; and proton pump inhibitors that cannot be switched to alternative treatment prior to enrolment.
  8. Known human immunodeficiency virus (HIV) infection.
  9. Acute or chronic hepatitis B or C infection.
  10. Women who are pregnant or in the period of lactation.
  11. Sexually active men and women of childbearing potential who are not willing to use an effective contraceptive method during the study.
  12. Judgement by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05673187


Contacts
Layout table for location contacts
Contact: Heidi Roschitzki, PhD +41 31 511 94 00 heidi.roschitzki@etop.ibcsg.org
Contact: Susanne Roux ADEPPT@etop.ibcsg.org

Locations
Show Show 22 study locations
Sponsors and Collaborators
ETOP IBCSG Partners Foundation
Mirati Therapeutics Inc.
Investigators
Layout table for investigator information
Study Chair: Jarushka Naidoo Beaumont RCSI Cancer Centre, Beaumont Hospital
Layout table for additonal information
Responsible Party: ETOP IBCSG Partners Foundation
ClinicalTrials.gov Identifier: NCT05673187    
Other Study ID Numbers: ETOP 22-22
2022-002736-31 ( EudraCT Number )
First Posted: January 6, 2023    Key Record Dates
Last Update Posted: April 9, 2024
Last Verified: April 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Adagrasib
Antineoplastic Agents